Summary

PEGylated Drugs Market Research Report Information by Molecule (Macromolecular Drugs, Small Molecular Drugs and Lipid Nanoparticles (LNP) and Liposomes), by Application (Oncology, Neurology, Autoimmune Diseases, Haematology and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) Forecast till 2035

Overview of the Market
During the assessment period, the PEGylated Drugs Market is expected to grow at a noteworthy CAGR of 5.17%. The process by which covalent and non-covalent glycol polymer chains bind to bioactive substances such proteins, peptides, enzymes, oligonucleotides, and antibody fragments is known as pegylation. In a clinical setting, it is a safe method for boosting the therapeutic effectiveness of medications. Numerous FDA-approved pegylated medications are used in clinical settings.
The global pegylated market is expanding due to the rising prevalence of chronic illnesses, developments in biologics, and newly approved pegylated medications. The market is also constrained by high production costs, regulatory obstacles, and possible adverse consequences. However, the industry will have future development prospects due to customized medicine, expanding markets, and cutting-edge drug delivery technologies.
The study includes a thorough analysis of the pegylated antibody's advantages, market expansion, motivating factors, and difficulties. It also highlights the main players in the PEGylated Proteins Market, their contributions, and their advancements.
The development of biologics industries, the rise in the prevalence of diseases like cancer, and the expansion of pharmaceutical industries worldwide are the primary factors propelling the PEGylated Drugs Market. Furthermore, Canada's rising rates of chronic illnesses and cancer-related deaths will support the expansion of pegylated medications on the market.
Overview of Market Segments
The PEGylated Drugs Market is divided into three segments: region, indication, and molecule.
The market has been divided into three segments based on molecules: liposomes, lipid nanoparticles (LNP), macromolecular drugs, and small molecular drugs.
The global market for pegylated pharmaceuticals has been divided into several segments based on their respective applications, including autoimmune diseases, neurology, oncology, and hematology.
The market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies based on the distribution route.

Analysis by region
The global market for PEGylated drugs has been divided into four segments based on geography: North America, Europe, Asia-Pacific, and the rest of the world. The greatest market share in 2024 was held by North America, which is expected to grow to USD 8,969.41 million by 2035. Nonetheless, over the course of the forecast period, Asia-Pacific is anticipated to develop at the highest CAGR of 7.03%.
North America and South America make up the American market. The North American market is dominated by the United States and Canada. The market is expanding due to the increased occurrence of chronic illnesses like cancer.
The European government's investment and assistance in the fight against chronic illnesses is what is propelling the regional market's expansion. Western Europe and Eastern Europe are two further classifications for the European region. The United Kingdom, Italy, France, Spain, and the rest of Western Europe are also included in this category.
Key players
Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Biogen, BioMarin Pharmaceutical Inc., Coherus BioSciences, Enzon, and Leadiant Biosciences, Inc. are the companies that are involved in the PEGylated Drugs Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY .............................................................................................................. 18
2 MARKET INTRODUCTION ............................................................................................................ 20
2.1 DEFINITION ........................................................................................................................................... 20
2.2 SCOPE OF THE STUDY ......................................................................................................................... 20
2.3 RESEARCH OBJECTIVE ........................................................................................................................ 20
2.4 MARKET STRUCTURE .......................................................................................................................... 21
3 RESEARCH METHODOLOGY ...................................................................................................... 22
3.1 OVERVIEW ............................................................................................................................................. 22
3.2 DATA FLOW ........................................................................................................................................... 24
3.2.1 DATA MINING PROCESS ................................................................................................................... 24
3.3 PURCHASED DATABASE: .................................................................................................................... 25
3.4 SECONDARY SOURCES: ....................................................................................................................... 26
3.4.1 SECONDARY RESEARCH DATA FLOW: ............................................................................................... 27
3.5 PRIMARY RESEARCH: .......................................................................................................................... 28
3.5.1 PRIMARY RESEARCH DATA FLOW: ................................................................................................... 29
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ........................................................... 30
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE .................................................................................... 30
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................... 31
3.6.1 REVENUE ANALYSIS APPROACH ...................................................................................................... 31
3.7 DATA FORECASTING ........................................................................................................................... 32
3.7.1 DATA FORECASTING TYPE ............................................................................................................... 32
3.8 DATA MODELING ................................................................................................................................. 33
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............................................................................................. 33
3.8.2 DATA MODELING:............................................................................................................................. 34
3.9 TEAMS AND ANALYST CONTRIBUTION .......................................................................................... 37
4 MARKET DYNAMICS .................................................................................................................... 39
4.1 INTRODUCTION .................................................................................................................................... 39
4.2 DRIVERS ................................................................................................................................................. 40
4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ............................................................................ 40
4.2.2 ADVANCEMENTS IN BIOLOGICS ....................................................................................................... 40
4.2.3 RECENTLY APPROVED PEGYLATED DRUGS ....................................................................................... 40
4.3 RESTRAINTS ........................................................................................................................................... 42
4.3.1 HIGH PRODUCTION COSTS ............................................................................................................... 42
4.3.2 REGULATORY HURDLES .................................................................................................................... 43
4.3.3 POTENTIAL SIDE EFFECTS................................................................................................................ 43
4.4 OPPORTUNITY ...................................................................................................................................... 44
4.4.1 EMERGING MARKETS ....................................................................................................................... 44
4.4.2 INNOVATIVE DRUG DELIVERY SYSTEMS ........................................................................................... 45
4.4.3 PERSONALIZED MEDICINE ................................................................................................................ 45
5 MARKET FACTOR ANALYSIS ...................................................................................................... 46
5.1 PORTER'S FIVE FORCES MODEL ........................................................................................................ 46
5.1.1 THREAT OF NEW ENTRANTS ............................................................................................................ 46
5.1.2 BARGAINING POWER OF SUPPLIERS ................................................................................................. 47
5.1.3 THREAT OF SUBSTITUTES ................................................................................................................ 47
5.1.4 BARGAINING POWER OF BUYERS ...................................................................................................... 47
5.1.5 INTENSITY OF RIVALRY .................................................................................................................... 47
5.2 IMPACT OF COVID-19 ON THE GLOBAL PEGYLATED DRUGS MARKET .................................. 48
5.3 QUALITATIVE ANALYSIS ON ANTI-PEG ANTIBODIES AND IMPACT ON PEGYLATED DRUGS 50
6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE .......................................................... 52
6.1 OVERVIEW ............................................................................................................................................. 52
6.2 MACROMOLECULAR DRUGS ............................................................................................................. 54
6.2.1 PROTEIN AND PEPTIDE .................................................................................................................... 55
6.2.2 ENZYME .......................................................................................................................................... 56
6.2.3 APTAMER ........................................................................................................................................ 56
6.3 SMALL MOLECULAR DRUGS .............................................................................................................. 57
6.4 LIPID NANOPARTICLES (LNP) AND LIPOSOMES ........................................................................... 57
7 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION ...................................................... 58
7.1 OVERVIEW ............................................................................................................................................. 58
7.2 ONCOLOGY ............................................................................................................................................ 61
7.3 NEUROLOGY .......................................................................................................................................... 61
7.4 AUTOIMMUNE DISEASES .................................................................................................................... 62
7.5 HAEMATOLOGY ................................................................................................................................... 62
7.6 OTHERS ................................................................................................................................................... 63
8 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CAHNNEL .................................. 64
8.1 OVERVIEW ............................................................................................................................................. 64
8.2 HOSPITAL PHARMACY ....................................................................................................................... 66
8.3 ONLINE PHARMACY ............................................................................................................................ 66
8.4 RETAIL PHARMACY ............................................................................................................................. 67
9 GLOBAL PEGYLATED DRUGS MARKET, BY REGION ............................................................... 68
9.1 OVERVIEW ............................................................................................................................................. 68
9.2 NORTH AMERICA ................................................................................................................................. 70
9.2.1 US ................................................................................................................................................... 74
9.2.2 CANADA .......................................................................................................................................... 76
9.3 EUROPE ................................................................................................................................................... 78
9.3.1 GERMANY ........................................................................................................................................ 82
9.3.2 FRANCE ........................................................................................................................................... 84
9.3.3 UK ................................................................................................................................................... 85
9.3.4 ITALY ............................................................................................................................................... 87
9.3.5 SPAIN .............................................................................................................................................. 89
9.3.6 REST OF EUROPE ............................................................................................................................. 91
9.4 ASIA-PACIFIC ........................................................................................................................................ 93
9.4.1 CHINA ............................................................................................................................................. 96
9.4.2 INDIA ............................................................................................................................................... 98
9.4.3 JAPAN ............................................................................................................................................. 100
9.4.4 AUSTRALIA ...................................................................................................................................... 101
9.4.5 SOUTH KOREA ................................................................................................................................. 103
9.4.6 REST OF ASIA-PACIFIC ..................................................................................................................... 104
9.5 REST OF THE WORLD .......................................................................................................................... 107
9.5.1 MIDDLE EAST & AFRICA ................................................................................................................... 110
9.5.2 SOUTH AMERICA.............................................................................................................................. 112
9.5.2.1 BRAZIL ..................................................................................................................................... 114
9.5.2.2 MEXICO .................................................................................................................................... 115
9.5.2.3 ARGENTINA .............................................................................................................................. 117
9.5.2.4 REST OF SOUTH AMERICA ........................................................................................................ 119
10 COMPETITIVE LANDSCAPE ........................................................................................................ 122
10.1 INTRODUCTION .................................................................................................................................... 122
10.2 MARKET SHARE ANALYSIS, 2024 ...................................................................................................... 122
10.3 COMPETITOR DASHBOARD ............................................................................................................... 123
10.4 PUBLIC PLAYERS STOCK SUMMARY ................................................................................................ 124
10.5 CMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ................................................................... 125
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ........................................................................... 126
10.6.1 PRODUCT APPROVAL ....................................................................................................................... 126
10.6.2 PRODUCT EXPANSION ..................................................................................................................... 127
10.6.3 APPROVAL DENIED .......................................................................................................................... 127
10.6.4 PRODUCT DISCONTINUATION........................................................................................................... 127
10.6.5 AGREEMENT/ACQUISITION .............................................................................................................. 128
10.6.6 CLINICAL TRIAL FINDINGS ............................................................................................................... 128
11 COMPANY PROFILES .................................................................................................................. 129
11.1 AMGEN INC. ........................................................................................................................................... 129
11.1.1 COMPANY OVERVIEW ...................................................................................................................... 129
11.1.2 FINANCIAL OVERVIEW...................................................................................................................... 130
11.1.3 PRODUCTS OFFERED ........................................................................................................................ 131
11.1.4 KEY DEVELOPMENTS ....................................................................................................................... 131
11.1.5 SWOT ANALYSIS .............................................................................................................................. 132
11.1.6 KEY STRATEGIES ............................................................................................................................. 132
11.2 PFIZER INC. ............................................................................................................................................ 133
11.2.1 COMPANY OVERVIEW ...................................................................................................................... 133
11.2.2 FINANCIAL OVERVIEW...................................................................................................................... 135
11.2.3 PRODUCTS OFFERED ........................................................................................................................ 136
11.2.4 KEY DEVELOPMENTS ....................................................................................................................... 136
11.2.5 SWOT ANALYSIS .............................................................................................................................. 136
11.2.6 KEY STRATEGIES ............................................................................................................................. 137
11.3 BIOGEN ................................................................................................................................................... 138
11.3.1 COMPANY OVERVIEW ...................................................................................................................... 138
11.3.2 FINANCIAL OVERVIEW...................................................................................................................... 139
11.3.3 PRODUCTS OFFERED ........................................................................................................................ 140
11.3.4 KEY DEVELOPMENTS ....................................................................................................................... 140
11.3.5 KEY STRATEGIES ............................................................................................................................. 140
11.4 BAYER AG ............................................................................................................................................... 141
11.4.1 COMPANY OVERVIEW ...................................................................................................................... 141
11.4.2 FINANCIAL OVERVIEW...................................................................................................................... 142
11.4.3 PRODUCTS OFFERED ........................................................................................................................ 142
11.4.4 KEY DEVELOPMENTS ....................................................................................................................... 143
11.4.5 SWOT ANALYSIS .............................................................................................................................. 143
11.4.6 KEY STRATEGY ................................................................................................................................ 144
11.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED....................................................................... 145
11.5.1 COMPANY OVERVIEW ..................................................................................................................... 145
11.5.2 FINANCIAL OVERVIEW...................................................................................................................... 146
11.5.3 PRODUCT OFFERED .......................................................................................................................... 146
11.5.4 KEY DEVELOPMENTS ....................................................................................................................... 147
11.5.5 KEY STRATEGIES ............................................................................................................................. 147
11.6 NOVO NORDISK A/S ............................................................................................................................. 148
11.6.1 COMPANY OVERVIEW ...................................................................................................................... 148
11.6.2 FINANCIAL OVERVIEW...................................................................................................................... 149
11.6.3 PRODUCTS OFFERED ........................................................................................................................ 150
11.6.4 KEY DEVELOPMENTS ....................................................................................................................... 150
11.6.5 SWOT ANALYSIS .............................................................................................................................. 151
11.6.6 KEY STRATEGIES ............................................................................................................................. 151
11.7 SANDOZ GROUP AG ............................................................................................................................. 152
11.7.1 COMPANY OVERVIEW ...................................................................................................................... 152
11.7.2 FINANCIAL OVERVIEW...................................................................................................................... 153
11.7.3 PRODUCTS OFFERED ........................................................................................................................ 154
11.7.4 KEY DEVELOPMENTS ....................................................................................................................... 154
11.7.5 KEY STRATEGIES ............................................................................................................................. 154
11.8 ASTRAZENECA ...................................................................................................................................... 155
11.8.1 COMPANY OVERVIEW ...................................................................................................................... 155
11.8.2 FINANCIAL OVERVIEW...................................................................................................................... 156
11.8.3 PRODUCTS OFFERED ........................................................................................................................ 157
11.8.4 KEY DEVELOPMENTS ....................................................................................................................... 157
11.8.5 KEY STRATEGIES ............................................................................................................................. 157
11.9 COHERUS BIOSCIENCES, INC. ............................................................................................................ 158
11.9.1 COMPANY OVERVIEW ...................................................................................................................... 158
11.9.2 FINANCIAL OVERVIEW...................................................................................................................... 159
11.9.3 PRODUCTS OFFERED ........................................................................................................................ 160
11.9.4 KEY DEVELOPMENTS ....................................................................................................................... 160
11.9.5 KEY STRATEGIES ............................................................................................................................. 160
11.10 F. HOFFMANN-LA ROCHE LTD. ......................................................................................................... 161
11.10.1 COMPANY OVERVIEW .......................................................................................................... 161
11.10.2 FINANCIAL OVERVIEW ......................................................................................................... 162
11.10.3 PRODUCTS OFFERED ........................................................................................................... 163
11.10.4 KEY DEVELOPMENTS ........................................................................................................... 163
11.10.5 SWOT ANALYSIS ................................................................................................................. 163
11.10.6 KEY STRATEGIES ................................................................................................................. 164
11.11 JOHNSON & JOHNSON INC. ................................................................................................................ 165
11.11.1 COMPANY OVERVIEW .......................................................................................................... 165
11.11.2 FINANCIAL OVERVIEW ......................................................................................................... 166
11.11.3 PRODUCTS OFFERED ........................................................................................................... 167
11.11.4 KEY DEVELOPMENTS ........................................................................................................... 167
11.11.5 SWOT ANALYSIS ................................................................................................................. 167
11.11.6 KEY STRATEGIES ................................................................................................................. 168
11.12 ALNYLAM PHARMACEUTICALS, INC. .............................................................................................. 169
11.12.1 COMPANY OVERVIEW .......................................................................................................... 169
11.12.2 FINANCIAL OVERVIEW ......................................................................................................... 170
11.12.3 PRODUCTS OFFERED ........................................................................................................... 170
11.12.4 KEY DEVELOPMENTS ........................................................................................................... 171
11.12.5 KEY STRATEGIES ................................................................................................................. 171
11.13 LES LABORATOIRES SERVIER ............................................................................................................ 172
11.13.1 COMPANY OVERVIEW .......................................................................................................... 172
11.13.2 FINANCIAL OVERVIEW ......................................................................................................... 172
11.13.3 PRODUCT OFFERED ............................................................................................................. 173
11.13.4 KEY DEVELOPMENTS ........................................................................................................... 173
11.13.5 KEY STRATEGIES ................................................................................................................. 173
12 DATA CITATIONS ......................................................................................................................... 174